🇺🇸 FDA
Pipeline program

SELUMETINIB, SELUMETINIB, Selumetinib, Selumetinib

SPRINKLE D1346C00004

Phase 2 small_molecule active

Quick answer

SELUMETINIB, SELUMETINIB, Selumetinib, Selumetinib for Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials